Related Experiment Video

Updated: Aug 3, 2025

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

33.7K

SRPKs: a promising therapeutic target in cancer

Muhammad Tufail1, Changxin Wu2

  • 1Institute of Biomedical Sciences, Shanxi University, Taiyuan, 030006, China. mtufail0276@gmail.com.

Clinical and Experimental Medicine
|April 7, 2023
PubMed

Insights

Dysregulation of serine/arginine repetitive protein kinases (SRPKs) is linked to common cancers. Targeting SRPKs shows promise for cancer treatment and overcoming resistance, though further research is needed.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Serine/arginine repetitive protein kinases (SRPKs) play a crucial role in cellular processes.
  • Dysregulation of SRPKs has been implicated in the development and progression of various cancers, including lung, breast, colon, and prostate cancers.
  • SRPKs are increasingly recognized for their involvement in cancer resistance mechanisms.

Purpose of the Study:

  • To review the multifaceted role of SRPKs in common human cancers.
  • To elucidate the contribution of SRPKs to cancer therapeutic resistance.
  • To explore the potential of targeting SRPKs as a novel strategy for cancer treatment.

Main Methods:

  • Literature review of preclinical and clinical studies on SRPKs in cancer.
  • Analysis of the molecular mechanisms underlying SRPK involvement in cancer cell growth, survival, and resistance.
  • Examination of current and emerging therapeutic strategies targeting SRPKs.

Main Results:

  • Inhibition of SRPKs has demonstrated significant reduction in cancer cell growth and survival in preclinical models.
  • Specific SRPKs have been identified as critical drivers in distinct cancer types.
  • SRPK inhibitors are being developed as potential therapeutic agents, with ongoing research into combination therapies.

Conclusions:

  • SRPKs represent promising therapeutic targets for a range of cancers.
  • Targeting SRPKs may offer a viable strategy to overcome cancer treatment resistance.
  • Further investigation is essential to optimize SRPK-targeted therapies and improve patient outcomes.
Keywords:
Breast cancerCancerColon cancerLung cancerProstate cancerSRPKs

More Related Videos

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

503
Studying RNA Interactors of Protein Kinase RNA-Activated during the Mammalian Cell Cycle10:05

Studying RNA Interactors of Protein Kinase RNA-Activated during the Mammalian Cell Cycle

Published on: March 5, 2019

6.5K

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.2K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.6K